CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 240 enrolled
Drug / intervention
Patients treated for their lung cancer.device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04934865
NCT04934865N/ACompleted

Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

Institut Curie·interventional·Posted Jun 22, 2021·Updated Mar 12, 2025

In Brief

A clinical study evaluating Patients treated for their lung cancer. for Lung Cancer. Completed, enrolled 240 participants across 15 sites.

Detailed Summary

Evaluation of patient's proportion, whose management care has been modified at least once and specially by Moovcare® Lung application at 12 and 24 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJun 22, 2021
Enrollment StartOct 7, 2021
Primary CompletionFeb 28, 2025
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5.0 years ago

Interventions

Patients treated for their lung cancer.device

In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart. In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator.